<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639804</url>
  </required_header>
  <id_info>
    <org_study_id>IN_APA_117</org_study_id>
    <nct_id>NCT04639804</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetic Interaction Between Tegoprazan and Non-steroidal Anti-inflammatory Drugs (NSAIDs) After Multiple Oral Dosing in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the pharmacokinetic (PK) interaction between tegoprazan and&#xD;
      non-steroidal anti-inflammatory drugs (NSAIDs) after given each alone and in their&#xD;
      combination in healthy male adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, multiple-dose, 6-sequence-arm, 3-period cross-over study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2020</start_date>
  <completion_date type="Actual">July 29, 2020</completion_date>
  <primary_completion_date type="Actual">July 26, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ of tegoprazan and NSAIDs</measure>
    <time_frame>pre-dose (0 hour) on Day1, Day5, Day6 and pre-dose up to 24 hours post-dose on Day7</time_frame>
    <description>Area under the plasma concentration-time curve during a steady-state dosing interval (τ) of tegoprazan and NSAIDs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Css,max of tegoprazan and NSAIDs</measure>
    <time_frame>pre-dose (0 hour) on Day1, Day5, Day6 and pre-dose up to 24 hours post-dose on Day7</time_frame>
    <description>Maximum Plasma Concentration at Steady State of tegoprazan and NSAIDs</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tegoprazan 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple doses of tegoprazan alone once daily (QD) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAIDs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple doses of NSAIDs alone twice daily (BID) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegoprazan 50 mg + NSAIDs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple doses of tegoprazan QD in combination with NSAIDs BID for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan</intervention_name>
    <description>Tegoprazan 50 mg tablet</description>
    <arm_group_label>Tegoprazan 50 mg</arm_group_label>
    <arm_group_label>Tegoprazan 50 mg + NSAIDs</arm_group_label>
    <other_name>K-CAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Naproxen 500 mg tablet</description>
    <arm_group_label>NSAIDs</arm_group_label>
    <arm_group_label>Tegoprazan 50 mg + NSAIDs</arm_group_label>
    <other_name>Naxen-F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aceclofenac</intervention_name>
    <description>Aceclofenac 100 mg tablet</description>
    <arm_group_label>NSAIDs</arm_group_label>
    <arm_group_label>Tegoprazan 50 mg + NSAIDs</arm_group_label>
    <other_name>Airtal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 200 mg capsule</description>
    <arm_group_label>NSAIDs</arm_group_label>
    <arm_group_label>Tegoprazan 50 mg + NSAIDs</arm_group_label>
    <other_name>Celebrex 200 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult aged ≥ 19 and &lt; 55 year-old at screening&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 19.0 kg/m2 and &lt; 27.0 kg/m2 with a body weight ≥ 55 kg at&#xD;
             screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or evidence of clinically significant disease&#xD;
&#xD;
          -  History of GI disease or surgery that may affect the absorption of a drug&#xD;
&#xD;
          -  Laboratory test result which falls into the following values( ALT or AST &gt; 2 × upper&#xD;
             limit of normal (ULN))&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 210 g/week within 6 months&#xD;
&#xD;
          -  Daily use of ≥ 20 cigarettes within 6 months&#xD;
&#xD;
          -  Has taken any investigational agent within 6 months prior to the first dose of IMP&#xD;
&#xD;
          -  Subjects who are considered ineligible to participate in this study at the discretion&#xD;
             of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk university hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-drug interaction</keyword>
  <keyword>pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Aceclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

